HC Wainwright Has Bearish Estimate for REGENXBIO Q1 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for REGENXBIO in a research note issued on Monday, March 9th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of ($1.23) for the quarter, down from their prior estimate of ($1.21). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2026 earnings at ($1.23) EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at ($1.24) EPS and FY2026 earnings at ($3.38) EPS.

RGNX has been the topic of a number of other research reports. Stifel Nicolaus lifted their target price on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, December 19th. UBS Group reaffirmed an “overweight” rating and set a $18.00 price objective on shares of REGENXBIO in a research report on Tuesday, February 10th. Morgan Stanley lowered their target price on REGENXBIO from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Leerink Partners boosted their price objective on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Finally, Wall Street Zen cut REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

REGENXBIO Trading Down 4.6%

Shares of NASDAQ RGNX opened at $9.90 on Wednesday. REGENXBIO has a 1 year low of $5.03 and a 1 year high of $16.19. The firm has a market capitalization of $510.94 million, a PE ratio of -2.63 and a beta of 1.08. The firm’s 50-day moving average is $11.31 and its 200-day moving average is $11.46.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). The company had revenue of $30.34 million for the quarter, compared to the consensus estimate of $45.48 million. REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.

Institutional Trading of REGENXBIO

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in shares of REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after purchasing an additional 594,161 shares during the period. Assenagon Asset Management S.A. increased its position in REGENXBIO by 64.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock valued at $16,709,000 after buying an additional 454,977 shares in the last quarter. Invenomic Capital Management LP acquired a new position in REGENXBIO during the 3rd quarter worth approximately $4,120,000. Integral Health Asset Management LLC boosted its holdings in REGENXBIO by 57.1% in the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $10,615,000 after acquiring an additional 400,000 shares in the last quarter. Finally, State Street Corp grew its stake in REGENXBIO by 15.2% in the fourth quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock valued at $32,929,000 after acquiring an additional 301,858 shares during the period. Institutional investors own 88.08% of the company’s stock.

Trending Headlines about REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and a $30 price target and raised its FY2026 EPS forecast (from -$3.63 to -$3.38) and materially boosted Q3 2026 to $0.31, signaling conviction in a mid‑year recovery and providing a bullish valuation anchor.
• Positive Sentiment: RBC Capital reiterated its Buy on RGNX, supporting the view that some sell‑side firms still see meaningful upside from current levels. RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX)
• Neutral Sentiment: HC Wainwright trimmed its $32 target to $30 (small change in absolute terms versus current price), a minor technical update rather than a change in stance. Benzinga
• Neutral Sentiment: Sector note — uniQure’s shares jumped after news of an FDA gene‑therapy official’s departure, highlighting how regulatory personnel moves can shift sentiment across gene‑therapy names (may influence perception of RGNX but not company‑specific fundamentals). uniQure shares jump after FDA gene therapy chief’s departure
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates (Q1, Q2 and Q4 2026 were revised lower), which signals tougher near‑term financials and could pressure the stock until visibility improves.
• Negative Sentiment: Multiple law firms have filed or are soliciting clients in securities‑class actions against REGENXBIO (Rosen, Pomerantz, Faruqi, Schall, Levi & Korsinsky, Gross, Bronstein, etc.). The wave of litigation and related notices increases legal and settlement risk and is a key negative driver for investor sentiment. Representative notices: Rosen Law Firm notice Levi & Korsinsky note Pomerantz class action alert

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.